- Home
- PROK vs BME Comparison
PROK vs BME Comparison
Compare PROK & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- BME
- Stock Information
- Founded
- PROK 2015
- BME 2005
- Country
- PROK United States
- BME United States
- Employees
- PROK N/A
- BME N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- BME Trusts Except Educational Religious and Charitable
- Sector
- PROK Health Care
- BME Finance
- Exchange
- PROK Nasdaq
- BME Nasdaq
- Market Cap
- PROK 417.1M
- BME 486.1M
- IPO Year
- PROK N/A
- BME N/A
- Fundamental
- Price
- PROK $2.97
- BME $37.66
- Analyst Decision
- PROK Strong Buy
- BME
- Analyst Count
- PROK 4
- BME 0
- Target Price
- PROK $6.25
- BME N/A
- AVG Volume (30 Days)
- PROK 2.1M
- BME 34.0K
- Earning Date
- PROK 11-11-2025
- BME 01-01-0001
- Dividend Yield
- PROK N/A
- BME 6.26%
- EPS Growth
- PROK N/A
- BME N/A
- EPS
- PROK N/A
- BME 1.44
- Revenue
- PROK $527,000.00
- BME N/A
- Revenue This Year
- PROK $427.89
- BME N/A
- Revenue Next Year
- PROK N/A
- BME N/A
- P/E Ratio
- PROK N/A
- BME $28.37
- Revenue Growth
- PROK N/A
- BME N/A
- 52 Week Low
- PROK $0.46
- BME $35.53
- 52 Week High
- PROK $7.13
- BME $43.20
- Technical
- Relative Strength Index (RSI)
- PROK 55.05
- BME 57.68
- Support Level
- PROK $2.80
- BME $37.37
- Resistance Level
- PROK $3.28
- BME $37.84
- Average True Range (ATR)
- PROK 0.27
- BME 0.50
- MACD
- PROK 0.01
- BME -0.01
- Stochastic Oscillator
- PROK 57.52
- BME 65.07
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.